RxDoctor Payments Data

Rudolph Depersia, MD

Internal Medicine · West Deptford, NJNPI 1134161813

Payments from drug & device makers

$3,894in general payments, 2019–2025

Across 249 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$790
  • Amarin Pharma, Inc.$472
  • GSK$366
  • Astellas Pharma US Inc$294
  • Lilly USA, LLC$239
  • AstraZeneca$238
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,82998%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,894 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$157,417
Medicare patients
277
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$121,597
JardianceEmpagliflozin91$111,514
EliquisApixaban64$86,530
XareltoRivaroxaban24$31,067
FarxigaDapagliflozin Propanediol21$30,149
Tresiba Flextouch U-200Insulin Degludec24$25,492
TradjentaLinagliptin14$20,255
MyrbetriqMirabegron19$18,104
WegovySemaglutide12$16,576
EdarbiAzilsartan Medoxomil16$10,675
InvokanaCanagliflozin14$10,350
EdarbyclorAzilsartan Med/Chlorthalidone13$8,585
Pitavastatin Calcium17$8,385
Icosapent Ethyl15$8,317
VascepaIcosapent Ethyl13$7,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$790$138,173110 claims
Boehringer IngelheimJardiance, Tradjenta$103$131,769105 claims
PfizerEliquis$213$86,53064 claims
Johnson & JohnsonXarelto, Invokana$63$41,41738 claims
AstraZenecaFarxiga$238$30,14921 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$89$19,26029 claims
Astellas Pharma US IncMyrbetriq$294$18,10419 claims
AbbVieSynthroid$74$1,28456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Deptford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →